Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.
- DOI
- 10.1007/s00262-026-04365-4
- Published
- 2026 May 11
- Container
- Cancer immunology, immunotherapy : CII
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00262-026-04365-4,
title = {Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.},
author = {Radovich M and Wacker J and Solzak J and Tae H and Ribeiro JR and Maney T and Hancock B and Hamrick J and Sledge GW and Ahluwalia MS and Liu SV and Lou E and Subbiah V and Halmos B and Magee D and Spetzler DB},
year = {2026},
journal = {Cancer immunology, immunotherapy : CII},
doi = {10.1007/s00262-026-04365-4},
url = {https://doi.org/10.1007/s00262-026-04365-4}
}RIS
TY - JOUR TI - Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy. AU - Radovich M AU - Wacker J AU - Solzak J AU - Tae H AU - Ribeiro JR AU - Maney T AU - Hancock B AU - Hamrick J AU - Sledge GW AU - Ahluwalia MS AU - Liu SV AU - Lou E AU - Subbiah V AU - Halmos B AU - Magee D AU - Spetzler DB PY - 2026 JO - Cancer immunology, immunotherapy : CII DO - 10.1007/s00262-026-04365-4 UR - https://doi.org/10.1007/s00262-026-04365-4 ER -
APA
M, R., J, W., J, S., H, T., JR, R., T, M., B, H., J, H., GW, S., MS, A., SV, L., E, L., V, S., B, H., D, M., & DB, S. (2026). Broader gene representation by whole-exome sequencing improves accuracy of tumor mutational burden assessment for selection of pembrolizumab immunotherapy.. Cancer immunology, immunotherapy : CII. https://doi.org/10.1007/s00262-026-04365-4
Source records
- pubmed · retrieved 2026-09-26T22:38:05.221Z